tetano
Editor, Senior Moderator
Ann Rheum Dis. 2020 Apr 29. pii: annrheumdis-2020-217407. doi: 10.1136/annrheumdis-2020-217407. [Epub ahead of print]
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Matucci-Cerinic M[SUP]#[/SUP][SUP]1[/SUP], Bruni C[SUP]#[/SUP][SUP]2[/SUP], Allanore Y[SUP]3[/SUP], Clementi M[SUP]4,[/SUP][SUP]5[/SUP], Dagna L[SUP]6,[/SUP][SUP]7[/SUP], Damjanov NS[SUP]8[/SUP], de Paulis A[SUP]9[/SUP], Denton CP[SUP]10[/SUP], Distler O[SUP]11[/SUP], Fox D[SUP]12[/SUP], Furst DE[SUP]2,[/SUP][SUP]13[/SUP], Khanna D[SUP]14[/SUP], Krieg T[SUP]15[/SUP], Kuwana M[SUP]16[/SUP], Lee EB[SUP]17[/SUP], Li M[SUP]18[/SUP], Pillai S[SUP]19[/SUP], Wang Y[SUP]20[/SUP], Zeng X[SUP]21[/SUP], Taliani G[SUP]22[/SUP].
Author information
Abstract
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
? Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
KEYWORDS:
autoimmune diseases; hydroxychloroquine; scleroderma; systemic
PMID:32349982DOI:10.1136/annrheumdis-2020-217407
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Matucci-Cerinic M[SUP]#[/SUP][SUP]1[/SUP], Bruni C[SUP]#[/SUP][SUP]2[/SUP], Allanore Y[SUP]3[/SUP], Clementi M[SUP]4,[/SUP][SUP]5[/SUP], Dagna L[SUP]6,[/SUP][SUP]7[/SUP], Damjanov NS[SUP]8[/SUP], de Paulis A[SUP]9[/SUP], Denton CP[SUP]10[/SUP], Distler O[SUP]11[/SUP], Fox D[SUP]12[/SUP], Furst DE[SUP]2,[/SUP][SUP]13[/SUP], Khanna D[SUP]14[/SUP], Krieg T[SUP]15[/SUP], Kuwana M[SUP]16[/SUP], Lee EB[SUP]17[/SUP], Li M[SUP]18[/SUP], Pillai S[SUP]19[/SUP], Wang Y[SUP]20[/SUP], Zeng X[SUP]21[/SUP], Taliani G[SUP]22[/SUP].
Author information
Abstract
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
? Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
KEYWORDS:
autoimmune diseases; hydroxychloroquine; scleroderma; systemic
PMID:32349982DOI:10.1136/annrheumdis-2020-217407